Business
-
According to DPI developer Iconovo, the company has received a grant worth SEK 670,000 from the EU’s Innowwide initiative, which encourages small and medium-sized EU companies to enter international markets. The grant will fund a market study… Read more . . .
-
According to Silo Pharma, the US Patent and Trademark Office (USPTO) has indicated that it will issue a new patent on March 4, 2025 that will provide protection for Silo’s SPC-15 intranasal ketamine. The company… Read more . . .
-
Tiziana Life Sciences announced that it has contracted with CDMO Renaissance Lakewood for development services related to Tiziana’s intranasal foralumab anti-CD3 monoclonal antibody. According to Tiziana, the project includes optimization of the formulation and development… Read more . . .
-
Kyorin Pharmaceutical is paying an undisclosed fee for the option to license Japanese development and marketing rights to Cyrano Therapeutics’ CYR intranasal theophylline for the treatment of loss of smell, the companies said. A Phase… Read more . . .
-
The Coalition for Epidemic Preparedness Innovations (CEPI) is providing $5 million to inhaled RNA developer Ethris for development of spray-dried RNA vaccines for nasal delivery. Ethris said that it plans to focus initially on a… Read more . . .
-
According to ENA Respiratory, California-based non-profit organization Flu Lab is providing a $5 million investment to support a Phase 2 proof of concept study of the company’s INNA-051 intranasal dry powder TLR2/6 agonist for the treatment… Read more . . .
-
California-based startup Miist Therapeutics, which calls itself “a physics-based developer of inhaled medicines,” announced that it has raised $7 million in seed funding and is developing 2 candidates: MST-01 for smoking cessation and MST-02 for… Read more . . .
-
InvisiShield Technologies said that it will speed up its H5N1 / Pan-influenza intranasal antibodies development program in response to recent outbreaks of H5N1 avian flu in mammals. The company says that it can move quickly… Read more . . .
-
North Carolina-based Belhaven Biopharma announced that it has closed a funding round that raised $11 million for continued development of the company’s Nasdepi intranasal dry powder epinephrine for the treatment of anaphylaxis. The company said… Read more . . .
-
Vast Therapeutics announced that the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) has awarded the company $1,988,594 to support a 2-year project titled “Nebulized ALX1 as a treatment… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden